HK1250936A1 - 用於治療病毒感染的化合物和方法 - Google Patents
用於治療病毒感染的化合物和方法Info
- Publication number
- HK1250936A1 HK1250936A1 HK18110419.2A HK18110419A HK1250936A1 HK 1250936 A1 HK1250936 A1 HK 1250936A1 HK 18110419 A HK18110419 A HK 18110419A HK 1250936 A1 HK1250936 A1 HK 1250936A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compositions
- methods
- viral infections
- treating viral
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/052—Imidazole radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7279408P | 2008-04-03 | 2008-04-03 | |
US7279908P | 2008-04-03 | 2008-04-03 | |
US7442108P | 2008-06-20 | 2008-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1250936A1 true HK1250936A1 (zh) | 2019-01-18 |
Family
ID=41377864
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK14112051.5A HK1198516A1 (zh) | 2008-04-03 | 2014-11-28 | 用於治療病毒感染的化合物和方法 |
HK18110419.2A HK1250936A1 (zh) | 2008-04-03 | 2018-08-14 | 用於治療病毒感染的化合物和方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK14112051.5A HK1198516A1 (zh) | 2008-04-03 | 2014-11-28 | 用於治療病毒感染的化合物和方法 |
Country Status (7)
Country | Link |
---|---|
US (4) | US8404651B2 (zh) |
EP (1) | EP2271351A4 (zh) |
KR (3) | KR101806314B1 (zh) |
CN (3) | CN107753499A (zh) |
GB (1) | GB2471806B (zh) |
HK (2) | HK1198516A1 (zh) |
WO (1) | WO2009146123A2 (zh) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8076303B2 (en) * | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
KR101881596B1 (ko) | 2008-12-02 | 2018-07-24 | 웨이브 라이프 사이언시스 재팬 인코포레이티드 | 인 원자 변형된 핵산의 합성 방법 |
SG177564A1 (en) | 2009-07-06 | 2012-02-28 | Ontorii Inc | Novel nucleic acid prodrugs and methods of use thereof |
EP2611451A4 (en) * | 2010-08-30 | 2014-01-15 | Spring Bank Pharmaceuticals Inc | DESIGN OF OLIGONUCLEOTIDE ANALOGUES AS THERAPEUTIC AGENTS |
NZ607996A (en) * | 2010-09-22 | 2014-07-25 | Alios Biopharma Inc | Substituted nucleotide analogs |
WO2012039448A1 (ja) | 2010-09-24 | 2012-03-29 | 株式会社キラルジェン | 不斉補助基 |
WO2012154321A1 (en) | 2011-03-31 | 2012-11-15 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
EP2734208B1 (en) | 2011-07-19 | 2017-03-01 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
TW201329096A (zh) | 2011-09-12 | 2013-07-16 | Idenix Pharmaceuticals Inc | 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物 |
CN104321333A (zh) | 2012-03-21 | 2015-01-28 | 沃泰克斯药物股份有限公司 | 硫代氨基磷酸酯核苷酸前药的固体形式 |
WO2013142157A1 (en) | 2012-03-22 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
WO2013177195A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphate prodrugs for hcv infection |
EP2852604B1 (en) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
NZ702744A (en) | 2012-05-22 | 2016-12-23 | Idenix Pharmaceuticals Llc | D-amino acid compounds for liver disease |
UY34824A (es) | 2012-05-25 | 2013-11-29 | Janssen R & D Ireland | Nucleósidos de espirooxetano de uracilo |
EP2872485B1 (en) | 2012-07-13 | 2020-12-16 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
WO2014010718A1 (ja) | 2012-07-13 | 2014-01-16 | 株式会社新日本科学 | キラル核酸アジュバント |
KR102213609B1 (ko) | 2012-07-13 | 2021-02-08 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
US9192621B2 (en) | 2012-09-27 | 2015-11-24 | Idenix Pharmaceuticals Llc | Esters and malonates of SATE prodrugs |
EA030189B8 (ru) | 2012-10-08 | 2018-10-31 | Иденикс Фармасьютикалз Ллс | Аналоги 2'-хлоронуклеозидов для инфекции вгс |
WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
KR20150119924A (ko) * | 2013-02-18 | 2015-10-26 | 스프링 뱅크 파마슈티칼스, 인크. | 백신 애쥬번트 및 치료제로서의 짧은 올리고뉴클레오티드의 설계 |
US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
US9309275B2 (en) | 2013-03-04 | 2016-04-12 | Idenix Pharmaceuticals Llc | 3′-deoxy nucleosides for the treatment of HCV |
EP2970357A1 (en) | 2013-03-13 | 2016-01-20 | IDENIX Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
US9187515B2 (en) | 2013-04-01 | 2015-11-17 | Idenix Pharmaceuticals Llc | 2′,4′-fluoro nucleosides for the treatment of HCV |
US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
WO2015017713A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
WO2015108047A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
JPWO2015108046A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤 |
AU2015207773B2 (en) | 2014-01-16 | 2021-06-17 | Wave Life Sciences Ltd. | Chiral design |
WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
WO2016045642A1 (en) | 2014-09-28 | 2016-03-31 | National Institute Of Biological Sciences, Beijing | Polymeric bile acid derivatives inhibit hepatitis b and d virus and ntcp transport |
WO2016164625A1 (en) * | 2015-04-07 | 2016-10-13 | Spring Bank Pharmaceuticals, Inc. | Compositions and methods for the treatment of hcv infection |
CA2982125A1 (en) * | 2015-04-07 | 2016-10-13 | Spring Bank Pharmaceuticals, Inc. | Compositions and methods for the treatment of hbv infection |
CN107922455A (zh) * | 2015-07-02 | 2018-04-17 | 春季银行制药股份有限公司 | 用于治疗病毒感染的组合物和方法 |
WO2017011622A1 (en) * | 2015-07-14 | 2017-01-19 | Spring Bank Pharmaceuticals, Inc. | Compounds and compositions that induce rig-i-and other pattern recongnition receptors |
WO2017066797A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Trinucleotide mrna cap analogs |
JP2018530587A (ja) * | 2015-10-16 | 2018-10-18 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | mRNAキャップ類似体およびmRNAキャッピングの方法 |
US20190070212A1 (en) * | 2016-03-11 | 2019-03-07 | Spring Bank Pharmaceuticals, Inc. | Compounds and compositions for the treatment of infections |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
TW201821085A (zh) * | 2016-10-24 | 2018-06-16 | 美商春季銀行製藥公司 | 用於治療hbv感染的組合物及方法 |
CN110467646A (zh) * | 2018-05-09 | 2019-11-19 | 博瑞生物医药(苏州)股份有限公司 | 双核苷酸前体药物 |
CN113164506B (zh) * | 2018-12-06 | 2023-12-08 | 正大天晴药业集团股份有限公司 | 二核苷酸化合物及其前体药物 |
CN111484540B (zh) * | 2019-01-25 | 2023-09-08 | 博瑞生物医药(苏州)股份有限公司 | 含双核苷酸结构的化合物 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2705099B1 (fr) * | 1993-05-12 | 1995-08-04 | Centre Nat Rech Scient | Oligonucléotides phosphorothioates triesters et procédé de préparation. |
AU4156197A (en) * | 1996-08-21 | 1998-03-06 | Hybridon, Inc. | Oligonucleotide prodrugs |
US20020127598A1 (en) * | 2000-03-27 | 2002-09-12 | Wenqiang Zhou | Solution-phase combinatorial library synthesis and pharmaceutically active compounds produced thereby |
KR101201552B1 (ko) | 2000-10-18 | 2012-11-15 | 파마셋 인코포레이티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드 |
US6961942B1 (en) | 2000-11-06 | 2005-11-01 | Microsoft Corporation | Bluetooth TDI and winsock interface |
KR100991975B1 (ko) * | 2001-05-16 | 2010-11-04 | 미게닉스 인코포레이티드 | 핵산을 기본으로 하는 화합물 및 이의 사용방법 |
US20060074035A1 (en) * | 2002-04-17 | 2006-04-06 | Zhi Hong | Dinucleotide inhibitors of de novo RNA polymerases for treatment or prevention of viral infections |
US6641916B1 (en) | 2002-11-05 | 2003-11-04 | E. I. Du Pont De Nemours And Company | Poly(trimethylene terephthalate) bicomponent fibers |
US20040158054A1 (en) * | 2003-02-07 | 2004-08-12 | Wu Jim Zhen | Di-ribonucleotides as specific viral RNA-polymerase inhibitors for the treatment or prevention of viral infections |
CA2529311A1 (en) * | 2003-03-28 | 2004-10-07 | Pharmasset, Inc. | Compounds for the treatment of flaviviridae infections |
WO2006002231A1 (en) * | 2004-06-22 | 2006-01-05 | Biocryst Pharmaceuticals, Inc. | Aza nucleosides, preparation thereof and use as inhibitors of rna viral polymerases |
CN101072570A (zh) * | 2004-09-24 | 2007-11-14 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒、瘟病毒和肝炎病毒的方法和组合物 |
JP5089395B2 (ja) * | 2004-10-29 | 2012-12-05 | バイオクライスト ファーマシューティカルズ, インコーポレイテッド | 治療用フロピリミジンおよびチエノピリミジン |
EP1853617A1 (en) * | 2005-02-28 | 2007-11-14 | Genelabs Technologies, Inc. | Tricyclic-nucleoside prodrugs for treating viral infections |
CA2600359A1 (en) * | 2005-03-09 | 2006-09-09 | Idenix (Cayman) Limited | Nucleosides with non-natural bases as anti-viral agents |
US8076303B2 (en) * | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
US20070293904A1 (en) | 2006-06-20 | 2007-12-20 | Daniel Gelbart | Self-powered resonant leadless pacemaker |
CN102307889A (zh) * | 2008-12-23 | 2012-01-04 | 集润德斯股份公司 | 硫化剂及其用于寡核苷酸合成的用途 |
SG177564A1 (en) * | 2009-07-06 | 2012-02-28 | Ontorii Inc | Novel nucleic acid prodrugs and methods of use thereof |
-
2009
- 2009-04-03 CN CN201711051066.3A patent/CN107753499A/zh active Pending
- 2009-04-03 EP EP09755485.1A patent/EP2271351A4/en not_active Withdrawn
- 2009-04-03 CN CN2009801207783A patent/CN102123716B/zh not_active Expired - Fee Related
- 2009-04-03 KR KR1020167004420A patent/KR101806314B1/ko active IP Right Grant
- 2009-04-03 GB GB1018497.6A patent/GB2471806B/en not_active Expired - Fee Related
- 2009-04-03 KR KR1020107024633A patent/KR101620394B1/ko active IP Right Grant
- 2009-04-03 WO PCT/US2009/039424 patent/WO2009146123A2/en active Application Filing
- 2009-04-03 CN CN201310362314.1A patent/CN103816174B/zh not_active Expired - Fee Related
- 2009-04-03 KR KR1020177034740A patent/KR101927905B1/ko active IP Right Grant
-
2010
- 2010-10-04 US US12/897,389 patent/US8404651B2/en not_active Expired - Fee Related
-
2013
- 2013-03-13 US US13/800,931 patent/US9138442B2/en not_active Expired - Fee Related
-
2014
- 2014-11-28 HK HK14112051.5A patent/HK1198516A1/zh not_active IP Right Cessation
-
2015
- 2015-08-11 US US14/823,359 patent/US9539276B2/en not_active Expired - Fee Related
-
2016
- 2016-12-02 US US15/367,552 patent/US10376533B2/en not_active Expired - Fee Related
-
2018
- 2018-08-14 HK HK18110419.2A patent/HK1250936A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US9539276B2 (en) | 2017-01-10 |
US9138442B2 (en) | 2015-09-22 |
CN107753499A (zh) | 2018-03-06 |
US10376533B2 (en) | 2019-08-13 |
GB201018497D0 (en) | 2010-12-15 |
KR20160031021A (ko) | 2016-03-21 |
KR101620394B1 (ko) | 2016-05-12 |
KR101806314B1 (ko) | 2017-12-07 |
EP2271351A4 (en) | 2016-08-31 |
CN103816174B (zh) | 2017-12-05 |
KR20100132058A (ko) | 2010-12-16 |
CN102123716B (zh) | 2013-09-18 |
WO2009146123A2 (en) | 2009-12-03 |
CN103816174A (zh) | 2014-05-28 |
KR101927905B1 (ko) | 2018-12-11 |
US20110207690A1 (en) | 2011-08-25 |
US20170304344A1 (en) | 2017-10-26 |
GB2471806A (en) | 2011-01-12 |
US20130197066A1 (en) | 2013-08-01 |
US20160038527A1 (en) | 2016-02-11 |
KR20170137947A (ko) | 2017-12-13 |
US8404651B2 (en) | 2013-03-26 |
HK1198516A1 (zh) | 2015-05-15 |
GB2471806B (en) | 2012-12-19 |
EP2271351A2 (en) | 2011-01-12 |
CN102123716A (zh) | 2011-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1250936A1 (zh) | 用於治療病毒感染的化合物和方法 | |
HRP20190214T1 (hr) | Pripravci i metode za liječenje purpure | |
WO2011056650A9 (en) | Methods and compositions for treating and preventing viral infections | |
HK1225316A1 (zh) | 治療病毒感染的方法 | |
EP2361089A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED FUNCTION OF -SYNUCLEINE | |
GB0816679D0 (en) | Compounds for treating viral infections | |
EP2120561A4 (en) | COMPOSITIONS FOR TREATING BIOFILMS, AND METHODS FOR THEIR USE | |
EP2124985A4 (en) | METHOD AND COMPOSITIONS FOR TREATING NERVOUS ELEMENTS | |
IL210097A0 (en) | Compositions and methods for treating unfluenza | |
ZA201101055B (en) | Compositions and methods for treating osteoarthritis | |
EP2451795A4 (en) | COMPOSITIONS AND METHODS FOR IMPROVING THE EFFICACY OF A VIRUS | |
EP2282719A4 (en) | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | |
IL195272A0 (en) | Methods and compositions for the treatment of viral infections | |
EP2504428A4 (en) | METHOD AND COMPOSITIONS FOR TREATING OXALATE-MEDIATED SUFFERING | |
EP2355660A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | |
EP2429584A4 (en) | TREATMENT PROCEDURE AND COMPOSITIONS | |
EP2249789A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF XEROSOMY | |
EP2217573A4 (en) | TREATMENT AND PREVENTION OF VIRUS INFECTIONS | |
EP2663327A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS | |
ZA201202924B (en) | Compositions and methods for treating bacterial infections using ceftaroline | |
HK1167350A1 (zh) | 保護和治療神經損傷的方法和組合物 | |
EP2393506A4 (en) | METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES | |
EP2429290A4 (en) | COMPOUNDS AND METHODS FOR THE TREATMENT OF AIDS AND HIV INFECTIONS | |
ZA201205639B (en) | Compositions and methods for treating hepatitis b virus infection | |
IL217764A0 (en) | Methods and compositions for treating leukemia |